Aster Insights

Aster Insights™ (formerly M2GEN®) is a leading oncology-focused bioinformatics solutions company advancing precision medicine and transforming cancer care through clinical and molecular data and analytics tools. The company’s innovative dataset accelerates the discovery, development, and delivery of personalized therapies. Aster Insights is the only bioinformatics company that has lifetime, patient-consented longitudinal clinical data, coupled with whole exome (WES) and whole transcriptome (WTS) sequencing, for both tumor and germline data. Aster Insights’ Oncology Research Information Exchange Network® (ORIEN), an alliance of NCI-Designated cancer centers that gather de-identified and lifetime-consented clinical and genomic patient data for research purposes, enables a collaborative approach to medical product discovery. The Company was founded to operationalize the Total Cancer Care (TCC) protocol, a unique approach to studying patients throughout their lifetime. TCC is one the world’s largest observational research studies in cancer and provides a harmonized approach that links longitudinal clinical data with molecular information, enabling a much deeper understanding of a patient’s disease. It represents a true partnership with patients who donate their clinical data and biospecimens, so that we may learn from their experiences and develop evidence-based approaches to meet their needs. For more information, visit www.AsterInsights.com Our Mission: To connect patients to a cure by accelerating the discovery and delivery of precision medicine.